Evidence map›Paper›PMID 34070797›Full record

ArticleCancers2021

How Has Prostate Cancer Radiotherapy Changed in Italy between 2004 and 2011? An Analysis of the National Patterns-Of-Practice (POP) Database by the Uro-Oncology Study Group of the Italian Society of Radiotherapy and Clinical Oncology (AIRO).

Ercole Mazzeo, Luca Triggiani, Luca Frassinelli, Alessia Guarneri, Sara Bartoncini, Paolo Antognoni, Stefania Gottardo, Diana Greco, Simona Borghesi, Sara Nanni and 12 more

Abstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Ercole MazzeoRadiotherapy Unit, Oncology and Hematology Department, University Hospital of Modena, 41124 Modena, Italy.
Luca TriggianiRadiation Oncology Department, University and Spedali Civili Hospital, 25123 Brescia, Italy.
Luca FrassinelliRadiotherapy Unit, Oncology and Hematology Department, University Hospital of Modena, 41124 Modena, Italy.
Alessia GuarneriDepartment of Oncology, Radiation Oncology, Azienda Ospedaliero-Universitaria Città della Salute e Della Scienza, 10126 Turin, Italy.
Sara BartonciniDepartment of Oncology, Radiation Oncology, Azienda Ospedaliero-Universitaria Città della Salute e Della Scienza, 10126 Turin, Italy.
Paolo AntognoniRadiotherapy Deparment, ASST dei Sette Laghi-Ospedale di Circolo e Fondazione Macchi, 21100 Varese, Italy.ORCID 0000-0001-5301-6127
Stefania GottardoService of Radiotherapy, Istituito Clinico Sant'Ambrogio, 25123 Milan, Italy.
Diana GrecoRadiation Oncology Department, University and Spedali Civili Hospital, 25123 Brescia, Italy.
Simona BorghesiRadiation Oncology Unit of Arezzo-Valdarno, Azienda USL Toscana Sud Est, 52100 Arezzo, Italy.ORCID 0000-0002-6786-6795
Sara NanniRadiation Oncology Unit of Arezzo-Valdarno, Azienda USL Toscana Sud Est, 52100 Arezzo, Italy.
Alessio BruniRadiotherapy Unit, Oncology and Hematology Department, University Hospital of Modena, 41124 Modena, Italy.ORCID 0000-0003-1068-5958
Gianluca IngrossoRadiation Oncology Section, Department of Medicine and Surgery, University of Perugia, 06123 Perugia, Italy.ORCID 0000-0003-4380-6947
Rolando Maria D'AngelilloDepatment of Biomedicine and Prevention, Tor Vergata University of Rome, 00133 Rome, Italy.
Beatrice DettiUnit of Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, 50134 Florence, Italy.
Giulio FrancoliniUnit of Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, 50134 Florence, Italy.
Alessandro MagliDepartment of Radiation Oncology, Udine General Hospital, 33100 Udine, Italy.ORCID 0000-0002-7004-1938
Andrea Emanuele GueriniRadiation Oncology Department, University and Spedali Civili Hospital, 25123 Brescia, Italy.
Stefano ArcangeliDepartment of Radiation Oncology, S. Gerardo Hospital-University of Milan Bicocca, 20900 Monza, Italy.
Luigi SpiazziDepartment of Medical Physics, Spedali Civili Hospital, 25123 Brescia, Italy.
Umberto RicardiDepartment of Oncology, Radiation Oncology, University of Turin, 10126 Turin, Italy.
Frank LohrRadiotherapy Unit, Oncology and Hematology Department, University Hospital of Modena, 41124 Modena, Italy.ORCID 0000-0003-1014-5556
Stefano Maria MagriniRadiation Oncology Department, University and Spedali Civili Hospital, 25123 Brescia, Italy.ORCID 0000-0002-4126-733X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeTwo previous "Patterns Of Practice" surveys (POP I and POP II), including more than 4000 patients affected by prostate cancer treated with radical external beam radiotherapy (EBRT) between 1980 and 2003, established a "benchmark" Italian data source for prostate cancer radiotherapy. This report (POP III) updates the previous studies.

methodsData on clinical management and outcome of 2525 prostate cancer patients treated by EBRT from 2004 to 2011 were collected and compared with POP II and, when feasible, also with POP I. This report provides data on clinical presentation, diagnostic workup, radiation therapy management, and toxicity as collected within the framework of POP III.

resultsMore than 50% of POP III patients were classified as low or intermediate risk using D'Amico risk categories as in POP II; 46% were classified as ISUP grade group 1. CT scan, bone scan, and endorectal ultrasound were less frequently prescribed. Dose-escalated radiotherapy (RT), intensity modulated radiotherapy (IMRT), image guided radiotherapy (IGRT), and hypofractionated RT were more frequently offered during the study period. Treatment was commonly well tolerated. Acute toxicity improved compared to the previous series; late toxicity was influenced by prescribed dose and treatment technique. Five-year overall survival, biochemical relapse free survival (BRFS), and disease specific survival were similar to those of the previous series (POP II). BRFS was better in intermediate- and high-risk patients treated with ≥ 76 Gy.

conclusionsThis report highlights the improvements in radiotherapy planning and dose delivery among Italian Centers in the 2004-2011 period. Dose-escalated treatments resulted in better biochemical control with a reduction in acute toxicity and higher but acceptable late toxicity, as not yet comprehensively associated with IMRT/IGRT. CTV-PTV margins >8 mm were associated with increased toxicity, again suggesting that IGRT-allowing for tighter margins-would reduce toxicity for dose escalated RT. These conclusions confirm the data obtained from randomized controlled studies.

Indexed as

Pattern Of Practiceprostate cancerradiotherapy

Identifiers

PMID34070797
PMCPMC8199007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.